title: (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
abstract: The current study examined the interaction between the cannabinoid CB(1) receptor agonists Delta(9)-tetrahydrocannabinol and (R)-methanandamide in combination with the cannabinoid CB(1) receptor antagonist SR-141716A (N-(piperidin-1-yl)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl) in rats responding for food on a fixed ratio (FR-10) schedule of food reinforcement. The study provided only limited evidence for antagonism by SR-141716A (at 1 mg/kg but not with 0.3, 3 and 10 mg/kg) of the rate suppressant effects induced by the cannabinoid CB(1) receptor agonist Delta(9)-tetrahydrocannabinol (and only at the single dose of 5.6 mg/kg Delta(9)-tetrahydrocannabinol). (R)-Methanandamide in combination with SR-141716A resulted in a greater rate suppression compared to that induced by (R)-methanandamide alone. Thus, SR-141716A augmented the rate-decreasing effects of (R)-methanandamide and only minimally altered the rate-decreasing effects of Delta(9)-tetrahydrocannabinol. Additionally, high doses (10 and 30 mg/kg) of SR-141716 singly consistently suppressed the rate of responding. The current results coupled with our previous data examining combinations of Delta(9)-tetrahydrocannabinol or (R)-methanandamide and SR-141716 (see text) underscore pharmacological/behavioral differences (whether quantitative or qualitative) between the cannabinoid CB(1) agonists (R)-methanandamide and Delta(9)-tetrahydrocannabinol revealed by their interactions with the cannabinoid CB(1) antagonist SR-141716.
authors.affiliation: Department of Psychiatry, MCP Hahnemann University, Philadelphia, PA 19102, USA.
authors.forename: Torbjörn U C
authors.initials: TU
authors.lastname: Järbe
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Lamb
authors.forename: Qian
authors.initials: Q
authors.lastname: Liu
authors.forename: Alexandros
authors.initials: A
authors.lastname: Makriyannis
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D003216:Conditioning, Operant / Q000187:drug effects*; D013759:Dronabinol / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000037:antagonists & inhibitors*; D000077285:Rimonabant
chemical_list: D001095:Arachidonic Acids; D006213:Hallucinogens; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C088155:methanandamide; D013759:Dronabinol; D000077285:Rimonabant